(Q39172509)

English

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.

scientific article published on 17 June 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

phase III clinical trial

0 references

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

Richard A Hubner

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Janusz A. Jankowski

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Jane M. Blazeby

3

object named as

Jane M Blazeby

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Susan J Dutton

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

David R Ferry

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Haider Abbas

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Asa Dahle-Smith

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Wasat Mansoor

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Joyce Thompson

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Mark Harrison

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Anirban Chatterjee

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Stephen Falk

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Angel Garcia-Alonso

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

David W Fyfe

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Tina Gamble

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Lynnda Peachey

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Mina Davoudianfar

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Sarah R Pearson

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Patrick Julier

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Rachel Kerr

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Russell D Petty

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

publication date

17 June 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

894-904

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Global patterns of cancer incidence and mortality rates and trends

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastroesophageal cancers: progress and problems

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Esophageal cancer: a critical evaluation of systemic second-line therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Unmet needs and challenges in gastric cancer: the way forward

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70024-5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950987%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39172509&oldid=1450159543"